Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai’s Global Brands Brisk but Sales Slip on Forex, Drug Price Revision
Eisai’s global brands were upbeat in the year through March 2017, but its group sales ticked down 1.6% over the previous year to 539,097 million yen owing to a biennial drug price revision in Japan and foreign exchange moves, the…
To read the full story
Related Article
- Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
- Eisai’s Half-Year Sales Grow on Global Brands, Profits Slide after EA Pharma One-Off Gain
November 2, 2017
- Eisai Plans Japan Filing for Lenvima’s HCC Indication in June: CEO
May 11, 2017
- Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
November 1, 2016
- Eisai Posts Higher Profits despite Sales Dip, Global Brands Expand
May 16, 2016
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…